Stephen Hoge - 27 Aug 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: President
Issuer ticker: MRNA
Reported as of: 27 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Aug 2026, 16:51:44 UTC
Prior SEC filing: 16 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ James Dillon, as Attorney-in-Fact

Key filing fact

Stephen Hoge filed Form 4 for Moderna, Inc. (MRNA) on 31 Aug 2026.

Key facts

This page summarizes Stephen Hoge's Form 4 filing for Moderna, Inc. (MRNA).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 31 Aug 2026, 16:51.

Change

Previous filing in this sequence was filed on 16 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001760669 Primary reporting owner

Hoge Stephen

Relationship: President
Address: C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
Signature: /s/ James Dillon, as Attorney-in-Fact
Signature date: 31 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,437
Change %: +0.1%
Price
Shares after: 1,485,285
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Tax liability

Transaction value
Shares: -695
Change %: -0.05%
Price: $149.66^*
Shares after: 1,484,590
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F2

MRNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +611
Change %: +0.04%
Price
Shares after: 1,485,201
Date: 28 Aug 2026
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Tax liability

Transaction value
Shares: -296
Change %: -0.02%
Price: $142.77^*
Shares after: 1,484,905
Date: 28 Aug 2026
Ownership: Direct
Footnotes: F2

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,116
Date: 27 Aug 2026
Ownership: By Valhalla, LLC

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 151,933
Date: 27 Aug 2026
Ownership: By Trust
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -1,437
Change %: -14%
Price: $0.000000^*
Shares after: 8,621
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,437
Exercise price
Footnotes: F1, F4

MRNA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -611
Change %: -33%
Price: $0.000000^*
Shares after: 1,221
Date: 28 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 611
Exercise price
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.

Footnote F3

These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F4

25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Footnote F5

25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.